文献速递胸部肿瘤

UV1端粒酶疫苗联合伊匹木单抗与纳武利尤单抗作为胸膜间皮瘤二线治疗的II期随机试验

UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial.
PubMed 文献 · Eur J Cancer · 2024-03-01

NIPU试验评估在伊匹木单抗联合纳武利尤单抗基础上加用端粒酶疫苗UV1治疗一线化疗后进展的胸膜间皮瘤患者。主要终点盲法独立中心评审(BICR)的无进展生存期(PFS)未达到:A组(联合UV1)中位PFS 4.2个月 vs B组(仅双免疫)4.7个月(HR 1.01,80%CI 0.75-1.36,P=0.979)。预设的缓解率分析支持加用疫苗。

要点

  • 主要终点BICR评估的PFS未达到,A组4.2个月 vs B组4.7个月(HR 1.01,P=0.979)。
  • 研究者评估的PFS:A组4.3个月 vs B组2.9个月(HR 0.60,80%CI 0.45-0.81,P=0.025)。
  • BICR确认的客观缓解率:A组31% vs B组16%(比值比2.44,80%CI 1.35-4.49,P=0.056)。

核心结论

  • 主要终点未达到;预设的缓解率分析支持加用UV1疫苗。

研究设计与样本

  • II期开放标签随机试验,纳入一线化疗后进展的胸膜间皮瘤患者,随机分为A组(伊匹木单抗+纳武利尤单抗+UV1)与B组(伊匹木单抗+纳武利尤单抗),共118例随机。
  • 主要终点为BICR评估的PFS;设检出HR 0.60需69个PFS事件,把握度80%,单侧α=0.10。

主要发现

  • 中位随访12.5个月(95%CI 9.7-15.6)时,BICR评估的中位PFS:A组4.2个月(95%CI 2.9-9.8)vs B组4.7个月(95%CI 3.9-7.0),HR 1.01(80%CI 0.75-1.36),P=0.979。
  • 研究者评估的中位PFS:A组4.3个月(95%CI 3.0-6.8)vs B组2.9个月(95%CI 2.4-5.5),HR 0.60(80%CI 0.45-0.81),P=0.025。
  • BICR确认的客观缓解率:A组31% vs B组16%,比值比2.44(80%CI 1.35-4.49),P=0.056。
  • 中位随访17.3个月(95%CI 15.8-22.9)时,总生存期:A组15.4个月(95%CI 11.1-22.6)vs B组11.1个月(95%CI 8.8-18.1),HR 0.73(80%CI 0.53-1.0),P=0.197。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 主要终点未达到。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The NIPU-trial investigates the effect of adding the telomerase vaccine UV1 to treatment with ipilimumab and nivolumab for patients with pleural mesothelioma (PM). METHODS: In this phase 2 open-label trial, patients with PM progressing after first-line chemotherapy were randomised to receive ipilimumab and nivolumab alone (arm B) or combined with UV1 (arm A). The primary endpoint was progression-free survival (PFS) as determined by BICR. It was estimated that 69 PFS events were needed to detect a hazard ratio (HR) of 0.60 with 80% power and a one-sided alpha level of 0.10. RESULTS: 118 patients were randomised. The median PFS determined by blinded independent central review (BICR) was 4.2 months (95%CI 2.9-9.8) in arm A and 4.7 months (95%CI 3.9-7.0) in arm B (HR 1.01, 80%CI 0.75-1.36 P = 0.979), after a median follow-up of 12.5 months (95%CI 9.7-15.6). The investigator-determined median PFS was 4.3 months (95%CI 3.0-6.8) in arm A and 2.9 months (95%CI 2.4-5.5) in arm B (HR 0.60, 80%CI 0.45-0.81 P = 0.025). Confirmed objective response rate (ORR) by BICR was 31% in arm A and 16% in arm B (odds ratio 2.44 80%CI 1.35-4.49 P = 0.056). After a median follow-up time of 17.3 months (95%CI 15.8-22.9), the OS was 15.4 months (95%CI 11.1-22.6) in arm A and 11.1 months (95%CI 8.8-18.1) in arm B, (HR 0.73, 80%CI 0.53-1.0, P = 0.197). CONCLUSION: The primary endpoint was not met. Predefined analyses of response rates are in favour of adding the vaccine.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Haakensen VD, Öjlert ÅK, Thunold S, et al. UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial. Eur J Cancer. 2024. PMID: 38447379. doi:10.1016/j.ejca.2024.113973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。